Damora Therapeutics, Inc. Operating Income Loss

• Damora Therapeutics, Inc. showed a decrease of -847.3% in Operating Income Loss from 2024 to 2025.
• This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Damora Therapeutics, Inc.'s Operating Income Loss has declined by 641.1%.
• Historical annual values: Fiscal year 2025: -$210.87 million | Fiscal year 2024: -$22.26 million | Fiscal year 2023: -$39.91 million | Fiscal year 2022: -$61.21 million | Fiscal year 2021: -$52.23 million | Fiscal year 2020: -$33.64 million | Fiscal year 2019: $38.97 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026